CTX340 not checked

CRISPR Therapeutics AG

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.”In the company’s words, NCT07758634 on ClinicalTrials.gov
Tested for
Hypertension
Main trialPhase 1/2
“A Study of CTX340 in Participants with Uncontrolled Hypertension.”In the company’s words, NCT07758634 on ClinicalTrials.gov

Other drugs for Hypertension

All 73 drugs for Hypertension

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 1 Jul 2028 A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CTX340

Following is part of Solo: you see every change to CTX340 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in